APA (7th ed.) Citation

R, A., VL, V., A, D., R, L., VK, T., V, P., . . . HN, A. R. (2026). Diosgenin-mediated NF-κB and MAPK pathway modulation for osteoarthritis treatment: Molecular mechanisms, bioavailability enhancement, and therapeutic applications. Inflammopharmacology, 34(2), 833. https://doi.org/10.1007/s10787-025-02102-4

Chicago Style (17th ed.) Citation

R, Adarkar, Viswambharan VL, Dessai A, Lobo R, Tippavajhala VK, Pai V, Subraya CK, and Aswatha Ram HN. "Diosgenin-mediated NF-κB and MAPK Pathway Modulation for Osteoarthritis Treatment: Molecular Mechanisms, Bioavailability Enhancement, and Therapeutic Applications." Inflammopharmacology 34, no. 2 (2026): 833. https://doi.org/10.1007/s10787-025-02102-4.

MLA (9th ed.) Citation

R, Adarkar, et al. "Diosgenin-mediated NF-κB and MAPK Pathway Modulation for Osteoarthritis Treatment: Molecular Mechanisms, Bioavailability Enhancement, and Therapeutic Applications." Inflammopharmacology, vol. 34, no. 2, 2026, p. 833, https://doi.org/10.1007/s10787-025-02102-4.